- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology ... | 1 | GlobeNewswire (USA) | ||
| 12.12.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11.25 | Artiva BioTherapeutics GAAP EPS of -$0.88 | 3 | Seeking Alpha | ||
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease | 214 | GlobeNewswire (Europe) | 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 151 | GlobeNewswire (Europe) | Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.10.25 | Cantor Fitzgerald reiterates Overweight rating on Artiva Biotherapeutics stock | 19 | Investing.com | ||
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.10.25 | Rheumatoide Arthritis: Artiva erhält FDA Fast-Track-Status für Zelltherapie AlloNK | 5 | Investing.com Deutsch | ||
| 16.10.25 | Artiva Biotherapeutics stock soars after FDA Fast Track designation | 2 | Investing.com | ||
| 16.10.25 | Artiva's AlloNK receives FDA Fast Track status for rheumatoid arthritis | 3 | Investing.com | ||
| 16.10.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | 370 | GlobeNewswire (Europe) | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
| 07.08.25 | Artiva Biotherapeutics GAAP EPS of -$0.87 misses by $0.06 | 2 | Seeking Alpha | ||
| 06.08.25 | Artiva Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.08.25 | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT ... | 189 | GlobeNewswire (Europe) | 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL... ► Artikel lesen | |
| 08.05.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights | 356 | GlobeNewswire (Europe) | IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis ... ► Artikel lesen | |
| 08.04.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer | 841 | GlobeNewswire (Europe) | SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies... ► Artikel lesen | |
| 24.03.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights | 252 | GlobeNewswire (Europe) | Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| MAINZ BIOMED | 1,200 | -1,64 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| TEMPUS AI | 51,00 | +0,99 % | Studie von Tempus AI belegt verbesserte Vorhersage für Krebs-Immuntherapie | ||
| BIOCRYST PHARMACEUTICALS | 5,586 | +0,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,360 | -0,73 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,230 | +0,44 % | SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,933 | +1,65 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | ||
| EXELIXIS | 35,060 | +0,49 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,800 | -0,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million | Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,370 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
ARTIVA BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,27 % bei einem Aktienkurs von 3,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.